about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

6 years ago
News Briefing

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

6 years ago
Cell/Gene Tx
FDA+

Dai­ichi Sankyo sinks $200M in­to new gene ther­a­py tech from Ul­tragenyx

6 years ago
Deals
Cell/Gene Tx

Mo­tion de­nied: Gilead still on the hook for $1.5B in dam­ages over CAR-T patent dis­pute with Bris­tol My­ers Squibb

6 years ago
People
Cell/Gene Tx

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

6 years ago
R&D
China

Un­fazed by dis­rup­tions, Cowen's in­vest­ment arm backs AM-Phar­ma's $176M piv­otal plan around lethal con­di­tion

6 years ago
Financing

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of ...

6 years ago
Coronavirus

Take­da antes up $44M for rare dis­ease pact, turn­ing to Ox­ford spin­out's ex­o­some tech

6 years ago
Deals

Cou­pling mR­NA with tR­NA and new de­liv­ery tech, MPM and Or­biMed help birth new $80M biotech in­to a slowed down world

6 years ago
Financing
Startups

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man ...

6 years ago
Coronavirus

Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

6 years ago
Deals
Discovery

Astel­las em­pow­ers new­ly en­er­gized Cy­tomX with $80M up­front to get pre­clin­i­cal bis­pe­cif­ic work go­ing

6 years ago
Deals
Discovery

Pfiz­er's JAK1 chal­lenger to Dupix­ent shines in an­oth­er PhI­II, but safe­ty is­sues still cast a shad­ow

6 years ago
R&D

New da­ta from ran­dom­ized tri­al dent HIV drug strat­e­gy against Covid-19

6 years ago
R&D
Coronavirus

Bay­er fires em­ploy­ee who was spot­ted break­ing quar­an­tine in Chi­na

6 years ago
China
Pharma

The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

6 years ago
Financing
Deals

Mer­ck touts PhI­II da­ta bur­nish­ing $500M plat­form — what kind of bar does it set for a chron­ic cough drug?

6 years ago
R&D

Covid-19 roundup — Re­gen­eron zooms in on cock­tail; BioN­Tech shares sky­rock­et on quick Pfiz­er al­liance

6 years ago
Coronavirus

Bio­gen staffer fled to Chi­na in search of emer­gency Covid-19 test­ing, care — and now faces crim­i­nal charges

6 years ago
People
Coronavirus

BioN­Tech teams up with Fo­s­un Phar­ma to test Covid-19 mR­NA vac­cine in Chi­na — and scores $50M in­vest­ment

6 years ago
R&D
Coronavirus

Part­nered with Gilead and Sanofi, pro­tein degra­da­tion spe­cial­ist Nurix bags $120M to chart its own clin­i­cal path

6 years ago
Financing

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

6 years ago
News Briefing

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

6 years ago
Deals

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

6 years ago
R&D
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times